Ovulation Inducing Drugs Industry Insights 2025 – Market Forecast for Executives and Planners
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Ovulation Inducing Drugs Market Size Changed, over the years?#_x000D_
The market size of ovulation-inducing drugs has seen steadfast growth in the past years. The projection is an increase from $4.42 billion in 2024 to $4.74 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. The substantial expansion in previous years can be tied to the creation of clomiphene citrate, the introduction of letrozole, regulatory certifications, market standardization, and the development of ovulation predictor kits._x000D_
_x000D_
#How Much Will the Ovulation Inducing Drugs Market Be Worth in 2029?#_x000D_
Anticipated to experience significant expansion in the coming years, the ovulation inducing drugs market is slated to reach $6.12 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth within the forecasted period can be ascribed to several factors such as evolving lifestyles, postponement of childbearing, incorporation of digital health, market expansion, increasing infertility rates, and tailored treatment plans. Key trends during this time frame are expected to be individualized treatment strategies, progress in reproductive endocrinology, non-intrusive fertility tracking, escalating demand for assisted reproductive technologies, and the creation of innovative drug formulations._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp_x000D_
_x000D_
#Which is the Largest Company in the Ovulation Inducing Drugs Market?#_x000D_
Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter PLC, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc._x000D_
_x000D_
#What Are the Main Market Drivers in the Ovulation Inducing Drugs Industry?#_x000D_
The escalating rates of female infertility are projected to spur the expansion of the ovulation-inducing drug market. Women’s infertility is a biological anomaly where a woman cannot get pregnant or maintain a pregnancy to full term, even after regular unprotected sexual activities over a considerable length of time, usually around a year or more. Ovulation-inducing drugs, designed to rectify irregular or non-existent ovulation, are employed as a remedy for this form of infertility. These medications stimulate the hormonal pathways involved in ovulation and encourage the ovaries to release fully developed eggs. For example, the Centers for Disease Control and Prevention, a government agency in the United States, forecasted that in 2022, around 6.1 million women aged between 15 and 44 in the US will have difficulties getting pregnant, representing 10% of the total female population. Furthermore, CCRM Management Company LLC, a medical management firm in the US, stated in June 2022 that infertility impacts 1 in 4 couples around the world on average and escalates by 5% to 10% each year. Consequently, the increasing incidence of women’s infertility acts as a catalyst for the growth in the sales of ovulation-inducing drugs. As an additional factor propelling the ovulation-inducing drugs market, there is an increasing number of patients choosing in-vitro fertilization (IVF). IVF is a series of intricate procedures aiding people and couples with fertility issues in achieving pregnancy. The application of ovulation-inducing drugs is a common IVF protocol, aiming to stimulate ovarian function and facilitate the production of multiple eggs for collection. These drugs are incorporated within the IVF treatment to maximize the probability of a successful outcome. For example, it was reported by The Society for Assisted Reproductive Technology, a US-based organization consisting of doctors and laboratory scientists, that in April 2024, there was a significant surge in egg-freezing cycles, rising from 24,560 in the previous year to 29,803 in 2022. Thus, the swelling numbers of patients resorting to IVF feed directly into the growth of the ovulation-inducing drugs market._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=13256&type=smp_x000D_
_x000D_
#How Is the Ovulation Inducing Drugs Market Segments Structured?#_x000D_
The ovulation inducing drugs market covered in this report is segmented –_x000D_
_x000D_
1) By Drug Class: Hormones, Therapeutics Drugs_x000D_
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration_x000D_
3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors_x000D_
2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine_x000D_
_x000D_
#What Strategic Trends Are Transforming the Ovulation Inducing Drugs Market?#_x000D_
Leading entities in the ovulation-induction medications sector are focusing on the development of groundbreaking drugs like Cetrorelix acetate, driving advancements in treatment for females experiencing controlled ovarian stimulation. Cetrorelix acetate for injection (cetrorelix) specifically acts as a gonadotropin-releasing hormone (GnRH) antagonist, blocking premature ovulation during in-vitro fertilization (IVF) procedures. In August 2022, a significant progression was made when Akorn Operating Company LLC, an American pharmaceutical firm, acquired FDA approval for their generic version of cetrorelix acetate for injection, 0.25mg (Cetrorelix). This is the first bioequivalent to the AP-rated Merck Serono Cetrotide that has received authorization. The major operating principle of Cetrorelix acetate is to act as a GnRH antagonist, thereby inhibiting the effects of GnRH. Notably, GnRH is instrumental in stimulating the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Moreover, Cetrorelix acetate is utilized to suppress premature LH surges among women experiencing controlled ovarian stimulation (COS), providing each egg the opportunity to mature fully._x000D_
_x000D_
#Access The Full Report Here:#_x000D_
_x000D_
#Which Global Regions Offer the Highest Growth in the Ovulation Inducing Drugs Market?#_x000D_
North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_
_x000D_
#Purchase The Full Report Today:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13256_x000D_
_x000D_
#This Report Delivers Insight On: #_x000D_
1. How big is the ovulation inducing drugs market, and how is it changing globally?_x000D_
2. Who are the major companies in the ovulation inducing drugs market, and how are they performing?_x000D_
3. What are the key opportunities and risks in the ovulation inducing drugs market right now?_x000D_
4. Which products or customer segments are growing the most in the ovulation inducing drugs market?_x000D_
5. What factors are helping or slowing down the growth of the ovulation inducing drugs market?_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 2071930708_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
